# First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin

> **NCT00982111** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 633 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin
- **BIOLOGICAL:** Necitumumab

## Key facts

- **NCT ID:** NCT00982111
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11-02
- **Primary completion:** 2012-11-14
- **Final completion:** 2020-12-23
- **Target enrollment:** 633 (ACTUAL)
- **Last updated:** 2022-01-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00982111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00982111, "First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00982111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*